newsfilter
← Latest News
Business Wire·

AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

Provided interim data at WORLDSymposium™ 2022 that showed sustained engraftment across first three patients 1+ year post-gene therapy in Phase 1/2 clinical triali for cystinosis; all remain off oral cysteamine to date Interim clinical data update o